Infant Bacterial Therapeutics AB (publ)

Stockholm Stock Exchange IBT-B.ST

Infant Bacterial Therapeutics AB (publ) Market Capitalization on January 14, 2025: USD 54.85 M

Infant Bacterial Therapeutics AB (publ) Market Capitalization is USD 54.85 M on January 14, 2025, a -59.96% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Infant Bacterial Therapeutics AB (publ) 52-week high Market Capitalization is USD 159.67 M on August 13, 2024, which is 191.08% above the current Market Capitalization.
Infant Bacterial Therapeutics AB (publ) 52-week low Market Capitalization is USD 41.47 M on October 02, 2024, which is -24.41% below the current Market Capitalization.
Infant Bacterial Therapeutics AB (publ) average Market Capitalization for the last 52 weeks is USD 95.37 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Stockholm Stock Exchange: IBT-B.ST

Infant Bacterial Therapeutics AB (publ)

CEO	Mr. Staffan Stromberg Ph.D.
IPO Date	March 29, 2016
Location	Sweden
Headquarters	Bryggargatan 10
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Key trends

Past 5 years